Related references
Note: Only part of the references are listed.2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Donna K. Arnett et al.
CIRCULATION (2019)
The Diabetes Gene and Wnt Pathway Effector TCF7L2 Regulates Adipocyte Development and Function
Xi Chen et al.
DIABETES (2018)
Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia
Whitney D. Maxwell et al.
PHARMACOTHERAPY (2017)
Association of genetic variations with pharmacokinetics and lipid-lowering response toatorvastatin in healthy Korean subjects
Hye In Woo et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
dbNSFP v3.0: A One-Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site SNVs
Xiaoming Liu et al.
HUMAN MUTATION (2016)
Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population
P. Kadam et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2016)
Seventeen years of statin pharmacogenetics: a systematic review
Maarten Leusink et al.
PHARMACOGENOMICS (2016)
The Ensembl Variant Effect Predictor
William McLaren et al.
GENOME BIOLOGY (2016)
Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Bruce K. Birmingham et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Lipid-lowering efficacy of atorvastatin
Stephen P. Adams et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
Molecular analysis of chylomicronemia in a clinical laboratory setting: Diagnosis of 13 cases of lipoprotein lipase deficiency
Jesus M. Martin-Campos et al.
CLINICA CHIMICA ACTA (2014)
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update
L. B. Ramsey et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review
William J. Canestaro et al.
GENETICS IN MEDICINE (2014)
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
Richard Haynes et al.
EUROPEAN HEART JOURNAL (2013)
Systemic Exposure to Atorvastatin Between Asian and Caucasian Subjects: A Combined Analysis of 22 Studies
Kuan Gandelman et al.
AMERICAN JOURNAL OF THERAPEUTICS (2012)
Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial
Daniel I. Chasman et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2012)
Statin-Associated Rhabdomyolysis: Is There a Dose-Response Relationship?
Anne Holbrook et al.
CANADIAN JOURNAL OF CARDIOLOGY (2011)
A framework for variation discovery and genotyping using next-generation DNA sequencing data
Mark A. DePristo et al.
NATURE GENETICS (2011)
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
D. Wang et al.
PHARMACOGENOMICS JOURNAL (2011)
Transporter Pharmacogenetics and Statin Toxicity
M. Niemi
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin
B. Tomlinson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
Yong Zhang et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2010)
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
Aaron McKenna et al.
GENOME RESEARCH (2010)
Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients
Miao Hu et al.
PHARMACOGENETICS AND GENOMICS (2010)
Effects of normalization on quantitative traits in association test
Liang Goh et al.
BMC BIOINFORMATICS (2009)
APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia
Jian Wang et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: A randomized, open-label, three-way crossover study
Yunxia Li et al.
CLINICAL THERAPEUTICS (2007)
PLINK: A tool set for whole-genome association and population-based linkage analyses
Shaun Purcell et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
Safety and efficacy of statins in Asians
James K. Liao
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Clinical implications of pharmacogenomics of statin treatment
L. M. Mangravite et al.
PHARMACOGENOMICS JOURNAL (2006)
Statin safety: A systematic review
M Law et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
E Lee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
A promoter polymorphism in cholesterol 7α-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin
K Kajinami et al.
ATHEROSCLEROSIS (2005)
Share Paper
